Avid Bioservices Inc (CDMO)

[entdoc]

Buying today is entirely appropriate given the gravity of the preclinical findings on Bavituximab effect on irradiation therapy results in lung cancer. This latest finding ALONE is enough to turn every head in the health industry. Why? For a "preclinical result? Because of the enormous mass of preclinical work on Bavituximab which has preceded this finding, and the utter consistency of transferring the same observations of safety and efficacy to humans from lower animal models. Admittedly in most cases Bavi in humans has not shown the gobsmacking effects seen in lower animals, there is no question in my mind that Bavi + irradiation, and/or Bavi + ANY cancer treatment could easily (and shoud) become standard of care. Huge. Obviously this could turn on a dime, as do many promising (or widely prescribed) medications. For the moment, I am not looking for backfilling of any stockprice gaps. We are not yet at the adjusted split level many of us bought at. Good luck to you who joined us today!
.